Vera DR. Galliumlabeled deferoxamine-galactos-yl-neoglycoalbumin: a radiopharmaceutical for regional measurement of hepatic receptor biochemistry[J]. J Nucl Med, 1992, 33(6): 1 160-1 166.
[5]
Yang WJ, Mou TT, Guo WY, et al. Fluorine-18 labeled galactosylated chitosan for asialoglycoprotein-receptor-mediated hepatocyte imaging[J]. Bioorganic & Medicinal Chemistry Letters, 2010, 20(16): 4 840-4 844.
[6]
Yang WJ, Mou TT, Peng C, et al. Fluorine-18 labeled galactosyl-neoglycoalbumin for imaging the hepatic asialoglycoprotein receptor[J]. Bioorganic & Medicinal Chemistry, 2009, 17(21): 7 510-7 516.
[7]
Liu S. 6-Hydrazinonicotinamide derivatives as bifunctional coupling agents for 99Tcm-labeling of small biomolecules[C]//Topics in Current Chemistry, Contrast Agents Ⅲ. Springer Berlin/Heidelberg, 2005: 117-153.
[8]
Ono M, Arano Y, Mukai T, et al. 99Tcm-HYNIC-derivatized ternary ligand complexes for 99Tcm-labeled polypeptides with low in vivo protein binding[J]. Nucl Med Biol, 2001, 28(3): 215-224.
[9]
Ono M, Arano Y, Mukai T, et al. Control of radioactivity pharmacokinetics of 99Tcm-HYNIC-labeled polypeptides derivatized with ternary ligand complexes[J]. Bioconjug Chem, 2002, 13(3): 491-501.
[10]
Ono M, Arano Y, Uehara T, et al. Intracellular metabolic fate of radioactivity after injection of technetium-99m-labeled hydrazino nicotinamide derivatized proteins[J]. Bioconjug Chem, 1999, 10(3): 386-394.
[11]
Abrams MJ, Juweid M, Tenkate CI, et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats[J]. J Nucl Med, 1990, 31(12): 2 022-2 028.
[12]
King TP, Zhao SW, Lam T. Preparation of protein conjugates via intermolecular hydrazone linkage[J]. Biochemistry, 1986, 25(19): 5 774-5 779.
[13]
Kokudo N, Vera DR, Makuuchi M. Clinical application of Tc-GSA[J]. Nucl Med Biol, 2003, 30(8): 845-849.
[14]
Stadalnik RC, Vera DR. The evolution of 99Tcm-NGA as a clinically useful receptor-binding radiopharmaceutical[J]. Nucl Med Biol, 2001, 28(5): 499-503.
[15]
Vera D, Hoh C, Stadalnik R. Radiopharmaceuticals for the study of liver and renal function[M]. Handbook of Radiopharmaceuticals. Chichester; John Wiley & Sons Ltd, 2003: 795-822.
[16]
Vera DR, Krohn KA, Stadalnik RC, et al. Tc-99m galactosyl-neoglycoalbumin: in vitro characterization of receptormediated binding[J]. J Nucl Med, 1984, 25(7): 779-787.
[17]
Vera DR, Stadalnik RC, Krohn KA. Technetium-99m galactosyl-neoglycoalbumin: preparation and preclinical studies[J]. J Nucl Med, 1985, 26(10): 1 157-1 167.
[18]
Kawa S, Hazama H, Kojima M, et al. A new liver function test using the asialoglycoproteinreceptor system on the liver cell membrane: II. Quantitative evaluation of labeled neoglycoprotein clearance [J]. J Nucl Med, 1986, 23(7): 907-916.
[19]
Kubota Y, Kojima M, Hazama H, et al. A new liver function test using the asialoglycoprotein-receptor system on the liver cell membrane: I. Evaluation of liver imaging using Tc-99m-neoglycoprotein[J]. Jpn J Nucl Med, 1986, 23(7): 899-905.
[20]
de Graaf W, Bennink RJ, Vetelainen R, et al. Nuclear imaging techniques for the assessment of hepatic function in liver surgery and transplantation[J]. J Nucl Med, 2010, 51(5): 742-752.
